Canopy Growth Corporation (CGC) vs Evolus, Inc. (EOLS)

Canopy Growth Corporation and Evolus, Inc. are both Drug Manufacturers Specialty & Generic companies. Evolus, Inc. is the larger, with a market value of $519.2M against $397.7M — 1.3× the size. Evolus, Inc. grew revenue faster over the last twelve months: 13.9% against 7.80%. Evolus, Inc. has the higher net margin (−10.9% vs −80.4%) and the higher return on invested capital (−14.5% vs −17.2%). Across the 17 metrics below, Evolus, Inc. leads on 14 and Canopy Growth Corporation on 3.

Valuation

Metric CGC EOLS Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 1.87 1.66 2.25
P/B 0.80 n/m 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m n/m 12.29
EV/Sales 1.52 2.02 2.56
Earnings yield (47.27%) (6.52%) (2.99%)
Free cash flow yield (15.29%) (4.17%) 0.00%

Profitability

Metric CGC EOLS Drug Manufacturers Specialty & Generic median
Gross margin 25.16% 66.74% 53.94%
Operating margin (54.89%) (5.90%) 0.00%
Net margin (80.39%) (10.85%) 0.00%
Free cash flow margin (28.34%) (6.92%) 0.00%
Return on equity (40.14%) 138.57% (0.40%)
Return on assets (23.54%) (14.40%) (3.32%)
Return on invested capital (17.19%) (14.47%) 0.00%

Growth

Metric CGC EOLS Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 7.80% 13.87% 10.01%
EPS growth (last fiscal year) 84.00% 1.23% —
Revenue growth, 5-year CAGR (13.04%) 39.36% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CGC EOLS Drug Manufacturers Specialty & Generic median
Debt to equity 0.35 (5.07) 0.05
Current ratio 3.04 1.70 2.31
Net debt to EBITDA 1.09 (4.08) 0.85

Dividend

Metric CGC EOLS Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric CGC EOLS Drug Manufacturers Specialty & Generic median
Market cap 397.66m 519.16m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack